To the full analysis
Elanco Animal Health stock: growth
ELANElanco Animal Health reported $4.72B in revenue for fiscal 2025, up 6.2% on the prior year, up 7.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4.9%
per year from 2015 to 2025, per share 1.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | |
|---|---|---|
| Revenue | 7.6% | 4.9% |
| Revenue per share | 5.1% | 1.5% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2015 | $2.91B | −$210.8M | −$93.5M |
| 2016 | $2.91B | −$47.9M | $45.6M |
| 2017 | $2.89B | −$310.7M | $75.2M |
| 2018 | $3.07B | $86.5M | $352.8M |
| 2019 | $3.07B | $67.9M | $26.7M |
| 2020 | $3.27B | −$560.1M | −$351.9M |
| 2021 | $4.76B | −$483M | $286M |
| 2022 | $4.41B | −$78M | $268M |
| 2023 | $4.42B | −$1.23B | $117M |
| 2024 | $4.44B | $338M | $394M |
| 2025 | $4.72B | −$232M | $284M |
Revenue by region
Where Elanco Animal Health Incorporated generates its revenue.
- Outside the US53%
- United States47%
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Outside the US | $1.58B | $1.55B | $1.8B | $2.64B | $2.45B | $2.43B | $2.4B | $2.48B | 52.6% |
| United States | $1.48B | $1.52B | $1.48B | $2.12B | $1.97B | $1.98B | $2.04B | $2.23B | 47.4% |
| Total revenue | $3.07B | $3.07B | $3.27B | $4.76B | $4.41B | $4.42B | $4.44B | $4.72B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.